Canaccord Genuity Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Bill Maughan maintains a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and raises the price target from $22 to $26.
March 04, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity has maintained a Buy rating on Y-mAbs Therapeutics and increased the price target from $22 to $26.
The upgrade in the price target by a reputable analyst firm like Canaccord Genuity typically signals a positive outlook on the stock, suggesting potential upside. This could lead to increased investor confidence and a possible short-term price increase for YMAB.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100